Cargando…

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the presence of t(9;22) chromosomal translocation that results in BCR-ABL fusion gene. ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib, are currently the front-line treatment options for C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Ming-Chin, Cheng, Hung-I, Hsu, Kate, Hsu, Yen-Ning, Kao, Chen-Wei, Chang, Yi-Fang, Lim, Ken-Hong, Chen, Caleb Gonshen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344416/ https://www.ncbi.nlm.nih.gov/pubmed/30705677 http://dx.doi.org/10.3389/fimmu.2018.03152

Ejemplares similares

Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia
por: Chang, Yu-Cheng, et al.
Publicado: (2021)

BAFF-driven NLRP3 inflammasome activation in B cells
por: Lim, Ken-Hong, et al.
Publicado: (2020)

Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma
por: Liu, Yu-Fan, et al.
Publicado: (2022)

The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
por: Hsu, Chao‐Chin, et al.
Publicado: (2021)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

Dasatinib in chronic myeloid leukemia: a review
por: Aguilera, Dolly G, et al.
Publicado: (2009)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
por: Lima, Lisa M, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Dasatinib Accelerates Valproic Acid-Induced Acute Myeloid Leukemia Cell Death by Regulation of Differentiation Capacity
por: Heo, Sook-Kyoung, et al.
Publicado: (2014)

Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer
por: Shen, Jiaying, et al.
Publicado: (2017)

Deciphering the biology of NKG2C+ natural killer cells
por: Rölle, Alexander
Publicado: (2015)

P1425: ACTIVATED AND EXPANDED NATURAL KILLER CELLS TRANSDUCED WITH AN NKG2D CHIMERIC ANTIGEN RECEPTOR AGAINST ACUTE MYELOID LEUKEMIA
por: Córdoba, L., et al.
Publicado: (2022)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
por: Haslam, Sonya
Publicado: (2005)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
por: Tarantini, Francesco, et al.
Publicado: (2019)

Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia
por: Kelly, Ryan L., et al.
Publicado: (2022)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
por: Serpa, Mariana, et al.
Publicado: (2010)

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
por: Kumagai, Takashi, et al.
Publicado: (2017)

Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report
por: LAI, SHIUE-WEI, et al.
Publicado: (2015)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

Cysteinyl leukotrienes mediate lymphokine killer activity induced by NKG2D and IL-15 in cytotoxic T cells during celiac disease
por: Tang, Fangming, et al.
Publicado: (2015)

Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case
por: Monge, Katia Sotelo, et al.
Publicado: (2015)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease
por: Stojanovic, Ana, et al.
Publicado: (2018)

Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Human Cytomegalovirus Glycoprotein UL16 Causes Intracellular Sequestration of NKG2D Ligands, Protecting Against Natural Killer Cell Cytotoxicity
por: Dunn, Claire, et al.
Publicado: (2003)

Natural adjuvants (PC and G2) induce activated natural killer cells with NKG2D expression and cytotoxic properties in colorectal cancer
por: khodadadi, Ali, et al.
Publicado: (2022)

Fluid shear stress enhances natural killer cell's cytotoxicity toward circulating tumor cells through NKG2D-mediated mechanosensing
por: Hu, Bing, et al.
Publicado: (2023)

Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8(+) T Cells: Mechanism of Immune Evasion
por: Lundholm, Marie, et al.
Publicado: (2014)

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study
por: Mizuta, Shuichi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_go5gesdij9rc706tps143i3j8l